DSIP Spray

The row below carries a price per mg figure: listed price divided by stated peptide content, excluding shipping and codes. It is the same calculation applied on every compound page, so a figure here is directly comparable to one anywhere else on the site.

We currently track a single listing for this compound. When a second vendor is added the rows are ordered by measured $/mg, and the flags for testing and shipping are computed from the data shown. Each row carries its own verification date.

Delta Sleep-Inducing Peptide — researched for deep sleep, stress reduction, and cortisol modulation.

DSIP is a naturally occurring nonapeptide discovered in 1974 that promotes delta wave sleep, reduces stress, and modulates multiple neurotransmitter systems including GABA and endogenous opioids.

DSIP is a naturally occurring nonapeptide discovered in 1974 that promotes delta wave sleep, reduces stress, and modulates multiple neurotransmitter systems including GABA and endogenous opioids. It has a molecular formula C35H48N10O15, mass 848.8 Da. Its published amino-acid sequence is Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. Common synonyms in the literature include Delta Sleep-Inducing Peptide, DSIP nonapeptide, and delta sleep peptide.

Investigation of DSIP to date is primarily preclinical, with the majority of citations concentrated in animal models and in-vitro assays rather than randomized controlled human trials. Published work referencing DSIP spans Sleep architecture studies: EEG studies in rabbits, rats, and limited human cohorts show DSIP increases delta wave (slow-wave) sleep duration without suppressing REM sleep. Unlike benzodiazepines, it enhances physiological sleep patterns rather than altering them, Chronic insomnia trials: European clinical studies (primarily 1980s-1990s) in patients with chronic insomnia reported improved sleep onset latency, reduced nocturnal awakenings, and enhanced subjective sleep quality. Schneider-Helmert (1983) reported significant improvements in 15 of 16 patients with psychophysiological insomnia, and Stress and HPA axis: DSIP reduces ACTH and cortisol secretion, suggesting anxiolytic and stress-protective properties. Research in alcohol and opioid withdrawal contexts showed DSIP reduced withdrawal symptom severity and normalized stress hormone levels. Proposed mechanisms in the literature include GABA system enhancement and NMDA receptor interaction. None of this material describes therapeutic outcomes in humans, and No vendor listed here provides dosing guidance for DSIP outside laboratory research.

For the full mechanistic profile, published references, and constraint notes on DSIP, see the DSIP research page. All references cited on that page are peer-reviewed primary literature.